Muzashvili T, Tutisani A, Chabradze G, Beridze N, Museridze N
Tbilisi Medical Academy after P. Shotadze, Georgia.
Georgian Med News. 2020 Feb(299):147-150.
Gastric cancer represents the fifth most common malignancy and third most common cause of cancer deaths worldwide. There are two major types of gastric carcinoma: enteric type and diffuse type. Diffuse type gastric cancer is frequently associated with the mutations in E-cadherin coding gene CDH1. In cases of CDH1 mutations complete gastrectomy is indicated. CDH1 mutations are reflected with CDH1 protein loss by immunohistochemistry. The relationship between CDH1 mutations and other markers of tumour aggressiveness, such as tumour proliferation index and the presence of p53 mutations and Her2 amplification is not well studied. Therefore, the aim of our study was to analyse the correlation between CDH1 loss and the expression of Ki67 proliferation marker, mutant oncoprotein p53 and Her2. Standard immunohistochemistry was used to detect the following antigens: CDH1 (MCH-38, Invitrogen), Ki67 (EP5, Bio SB), p53 (DO-7, Leica) and Her2 (EP3, Bio SB). The study results showed that CDH1 mutations, reflected with CDH1 protein loss by immunohistochemistry are detected in 40% of diffuse gastric carcinomas, whilst it is not detected in enteric type gastric carcinomas. Diffuse gastric carcinomas with CDH1 mutations are characterised with more aggressive phenotype, particularly with the presence of higher Ki67 labelling index, p53 mutations and the presence of Her2 positivity. In cases of histological diagnosis of diffuse gastric carcinoma CDH1 testing is recommended.
胃癌是全球第五大常见恶性肿瘤，也是癌症死亡的第三大常见原因。胃癌主要有两种类型：肠型和弥漫型。弥漫型胃癌常与E-钙黏蛋白编码基因CDH1的突变有关。对于CDH1突变的病例，建议行全胃切除术。通过免疫组化检测，CDH1突变表现为CDH1蛋白缺失。CDH1突变与其他肿瘤侵袭性标志物之间的关系，如肿瘤增殖指数、p53突变的存在以及Her2扩增，尚未得到充分研究。因此，我们研究的目的是分析CDH1缺失与Ki67增殖标志物、突变癌蛋白p53和Her2表达之间的相关性。采用标准免疫组化检测以下抗原：CDH1（MCH-38，Invitrogen）、Ki67（EP5，Bio SB）、p53（DO-7，Leica）和Her2（EP3，Bio SB）。研究结果显示，通过免疫组化检测到的CDH1蛋白缺失所反映的CDH1突变，在40%的弥漫型胃癌中存在，而在肠型胃癌中未检测到。具有CDH1突变的弥漫型胃癌具有更具侵袭性的表型，特别是具有更高的Ki67标记指数、p53突变以及Her2阳性。对于弥漫型胃癌的组织学诊断病例，建议进行CDH1检测。
